BioCryst Turns Orladeyo Profits Into Rare Disease Buying Spree

A Once-Struggling Biotech Finds Its Footing

BioCryst Pharmaceuticals spent decades cycling through the familiar biotech pattern of burning cash while chasing an approved medicine. That pattern broke in 2025. The company posted its first full year of profitability, and executives say the goal now is to convert that cash into a pipeline built largely through acquisitions rather than in-house science 1.

The turnaround centers on Orladeyo, an oral, once-daily pill that blocks plasma kallikrein to prevent the swelling attacks associated with hereditary angioedema, or HAE. The FDA approved the drug in 2020, and it has since become the commercial engine funding BioCryst's broader ambitions 1.

The Numbers Behind the Pivot

BioCryst's full-year 2025 results show why management feels emboldened. Orladeyo generated $601.8 million in net revenue, up 38% year over year, or 43% when excluding the European business the company sold off during the year 69. Total revenue reached $874.8 million, a figure inflated by a one-time $243.3 million licensing payment tied to the sale of BioCryst's European Orladeyo operations to Neopharmed Gentili S.p.A. 69. Stripped of that one-time item, non-GAAP revenue came in closer to $592.9 million 9.

More strikingly, the company swung from a $2.5 million operating loss in 2024 to $341.0 million in GAAP operating profit in 2025, with non-GAAP operating profit climbing 198% to $214.2 million 9. BioCryst ended the year with $337.5 million in cash, restricted cash and investments, and used the European sale proceeds to retire its Pharmakon debt 69. For 2026, the company is guiding to Orladeyo revenue of $625 million to $645 million and total revenue of $635 million to $660 million 612.

The European divestiture did more than pad the balance sheet — it sharpened BioCryst's identity as a U.S.-focused HAE company just as it was preparing its next major move 6.

Buying Astria: A Template for Dealmaking

That next move came in October 2025, when BioCryst agreed to acquire Astria Therapeutics in a cash-and-stock deal worth roughly $700 million, a premium of about 53% to 54% over Astria's prior closing price 1114. Astria shareholders received $8.55 in cash plus 0.59 BioCryst shares per share, implying a value of about $13 per share 1011. BioCryst funded the cash portion using cash on hand and a debt facility of up to $550 million arranged with funds managed by Blackstone 1011. The deal closed in January 2026 16.

The prize was navenibart, a long-acting monoclonal antibody that also inhibits plasma kallikrein but is designed for injection every three or six months rather than daily oral dosing 811. Earlier trial data pooled from the ALPHA-STAR and ALPHA-SOLAR studies showed roughly 92% mean reductions in HAE attacks sustained for up to two years in some patients 812. The pivotal Phase 3 ALPHA-ORBIT trial completed enrollment in June 2026, with top-line data now expected in the third quarter of 2027 813.

Analysts were divided on how to characterize the wager. Reuters described it as BioCryst deepening its rare-disease focus, while BioPharma Dive framed it as the company going "all in" on a single disease 1114. RBC Capital Markets analyst Brian Abrahams argued that buying a late-stage, partially de-risked asset was a smarter capital allocation than funding risky early-stage programs internally 1114. BioCryst projects the combined Orladeyo-navenibart HAE franchise could generate at least $1.8 billion in annual revenue by 2033 1114. Notably, both drugs target the same biological pathway and the same disease, meaning the acquisition diversified BioCryst's product lineup without yet diversifying its disease exposure 11.

The company also picked up an early-stage atopic dermatitis program, STAR-0310, through the deal, which it plans to shop for "strategic alternatives" rather than develop itself 1114. Astria CEO Jill Milne joined BioCryst's board following the close 11.

Shutting Down In-House Discovery

The more structurally significant announcement came several months later. In June 2026, BioCryst said it would wind down its internal drug-discovery programs entirely and close its Discovery Center of Excellence in Birmingham, Alabama, by the end of the year 131516. The decision followed a six-month strategic review and reflects a bet that licensing and acquiring outside science will be faster and more capital-efficient than building an internal research organization 1315.

The closure is not without cost to employees: a subsequent WARN filing disclosed that 47 jobs would be eliminated as part of the Birmingham shutdown 17. BioCryst framed the restructuring as also delivering savings, lowering its 2026 non-GAAP operating-expense guidance to $420 million–$440 million from a prior range of $450 million–$470 million 131617.

Despite ending internal discovery, BioCryst is continuing two clinical-stage programs: navenibart, and BCX17725, an investigational KLK5 inhibitor for Netherton syndrome, a severe and currently untreatable genetic skin disorder. Dosing is underway in a Phase 1 study of up to 12 patients, with proof-of-concept data expected by the end of 2026 131516.

Where AI and Gene Editing Fit In

BioCryst itself is not an AI-drug-discovery company or a gene-editing developer — its assets are a small-molecule inhibitor and an antibody, not CRISPR-based therapies. But the broader ecosystem it plans to shop in is increasingly shaped by both technologies.

AI is becoming embedded in how rare-disease science gets generated and financed. The newly launched Rare Ventures platform in Pittsburgh, backed by up to $25 million from the Richard King Mellon Foundation, pairs the EB Research Partnership with the University of Pittsburgh, UPMC, Carnegie Mellon and Stanford Medicine to combine patient data, AI and drug development into a single pipeline, initially spanning seven rare conditions 181920. Carnegie Mellon's contribution includes applying AI to detect disease-linked genetic variants and to computationally screen thousands of candidate chemical structures 20. Elsewhere, AI-native biotech startups continue to draw fresh venture capital — from Lady Gaga-backed Outer Bio's model trained on living human skin tissue 2, to Adaptive Biotechnologies co-founder Harlan Robins' new $15 million venture aimed at rethinking how AI trains on scientific data 5, to a wave of biotech-focused entrants in Y Combinator's latest cohort 3.

Gene editing adds a separate, more controversial dimension to the landscape. Reports of startups such as Manhattan Genomics and Preventive pursuing heritable embryo editing have reignited ethical debates reminiscent of the international backlash following He Jiankui's gene-edited babies experiment 4. That controversy sits apart from BioCryst's commercial calculus, but it underscores how contested and fast-moving gene-editing science has become as a category of potential biotech assets.

The Bigger Financing Story

BioCryst's approach reflects a broader shift in how rare-disease drugs get funded and commercialized. As large pharmaceutical companies increasingly chase only assets capable of $2 billion or more in peak sales, mid-sized commercial biotechs are emerging as buyers for promising but smaller rare-disease programs that would otherwise struggle to find a home. BioCryst's own executives have suggested the company could pursue drugs with peak sales potential as modest as $300 million, leveraging its existing sales infrastructure rather than building new commercial operations from scratch.

Whether that strategy proves durable depends on questions that remain unresolved: whether navenibart's Phase 3 results confirm its early promise, whether BioCryst can price acquisitions rationally without overleveraging its balance sheet, and whether its commercial engine can support drugs beyond hereditary angioedema. For now, BioCryst has demonstrated it can generate real profit from a single approved medicine. Turning that profit into a repeatable dealmaking machine — rather than a one-off success story — is the test still ahead.